Clinical trials: Myeloid Tumor
Acute Myeloid Leukemia
FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML
To determine the feasibility of fludarabine and cytarabine as continuous infusion plus idarubicin with granulocyte-colony stimulating factor priming for patients with resistant acute myeloid leukemia other than acute…
- Trial name
- NCT00559221
- Testing
- FLAG+IDA
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Cooperative Study Group A for Hematology
Leukemia, Myeloid, Acute
A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World
The aim of this observational study is to describe treatment patterns and effectiveness outcomes in a sample of oncology patients treated for AML with Mylotarg through up to two additional relapsed/refractory (R/R)-based lines of…
- Trial name
- NCT04337138
- Testing
- Gemtuzumab Ozogamicin
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Pfizer
Chronic Myeloid Leukemia, Minimal Residual Disease
Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease
The goal of this clinical research study is to learn if giving 1 of 2 CML (Chronic Myeloid Leukemia) vaccines (CML-VAX B2 or CML-VAX B3) together with imatinib mesylate can decrease or eliminate all evidence of disease in…
- Trial name
- NCT00267085
- Testing
- Synthetic Tumor-Specific Breakpoint Peptide Vaccine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myelodysplastic Syndromes
Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)
This is an open-label, two-arm, phase III non-inferiority trial to evaluate the safety of a liberalized hospital diet inclusive of fresh fruits and vegetables to a neutropenic diet in patients with prolonged neutropenia.
- Trial name
- NCT03016130
- Testing
- Diet
- Where
- United States
- Volunteers
- 217 people
- Sponsor
- University of Florida
Leukemia,Myeloid, Chronic
Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML
Gut microbiome (GM) is acquiring increasing importance in human health and disease. GM influences hematopoiesis and immune cells types differentiation. Patients with cancer are characterized by dysbiosis and compromised immunity.
- Trial name
- MICROBIO-LMC (NCT06724536)
- Testing
- non interventional study with the use of biological samples.
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Carmen Fava
Acute Myeloid Leukemia
Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
The purpose of this study is to investigate the combination of gemtuzumab ozogamicin, mitoxantrone and etoposide as second line therapy in patients with acute myeloid leukemia.
- Trial name
- NCT00660036
- Testing
- Gemtuzumab ozogamicin, Mitoxantrone, Etoposide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pittsburgh
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This pilot trial studies decitabine, donor natural killer cells, and aldesleukin in treating patients with acute myeloid leukemia that has come back after previous treatment (relapsed) or has not responded to previous treatment…
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT02316964
- Testing
- decitabine, natural killer cell therapy, aldesleukin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sumithira Vasu
Acute Myelogenous Leukemia, Multiple Myeloma
Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy
This is a prospective, multicenter observational study to collect clinically annotated biospecimens in order to assess the correlation between ex vivo data generated by the Notable assay platform and clinical outcome.
- Conditions
- Acute Myelogenous Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma
- Trial name
- (ANSWer) (NCT04014764)
- Testing
- This is a non-interventional study
- Where
- 20 sites in United States, Greece and 1 more
- Volunteers
- 119 people
- Sponsor
- Notable Labs
Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
Pharmacokinetics, Tolerability and Safety of NEX-18a
The study will evaluate the safety, tolerability and pharmacokinetics of NEX-18a, a long-acting injectable azacitidine, in patients diagnosed with intermediate 2 or higher-risk MDS, CMML, or AML and already on treatment with…
- Conditions
- Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML)
- Trial name
- NCT05048498
- Testing
- NEX-18a injection, Azacitidine Injection
- Where
- 2 sites in Sweden
- Volunteers
- 2 people
- Sponsor
- Nanexa AB
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome
The goal of this clinical research study is to learn if giving 5-aza-2 deoxycytidine (decitabine) in combination with Mylotarg (gemtuzumab ozogamicin) can help to control AML or high-risk MDS.
- Trial name
- NCT00968071
- Testing
- Decitabine, Gemtuzumab Ozogamicin
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia
This is one of the first studies of combination of Zarnestra plus Velcade in man. A primary objective of the study is therefore to assess the safety and tolerability of multiple doses of Zarnestra plus Velcade in patients with…
- Trial name
- HEMOS AML 0106 (NCT00510939)
- Testing
- Tipifarnib plus Bortezomib
- Where
- Italy
- Volunteers
- 72 people
- Sponsor
- University of Bologna
Acute Myeloid Leukemia
Higher Percentage of CD34+ CD38- Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predicts Unsustained Complete Remission in Acute Myeloid Leukemia
Over recent decades, improvements have been made in the treatment of adult acute myeloid leukemia (AML). This has been mainly attributed to improvements in supportive therapy and to intensification of treatment strategies.
- Trial name
- NCT02842112
- Testing
- PBSC mobilization and leukapheresis
- Where
- France
- Volunteers
- 123 people
- Sponsor
- Hospices Civils de Lyon
Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of ASTX727 and filgrastim for the treatment of children with high risk acute myeloid leukemia that has come back after a period of improvement (recurrent) or that…
- Conditions
- Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT07012044
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 15 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, AML
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML
The purpose of this study is to evaluate the efficacy and safety of tosedostat in elderly patients suffering from refractory or relapsed AML.
- Trial name
- OPAL (NCT00780598)
- Testing
- Tosedostat
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 76 people
- Sponsor
- Chroma Therapeutics
Chronic Myeloid Leukemia (CML)
Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.
This is an open label, non randomized, prospective, multicenter, phase II clinical trial evaluating nilotinib 400 mg BID for the treatment of newly diagnosed CML-AP patients.
- Trial name
- MACS1881 (NCT01605981)
- Testing
- AMN107
- Where
- 18 sites in Brazil
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myelocytic, Acute, Leukemia
Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission
Evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation for AML.
- Conditions
- Leukemia, Myelocytic, Acute, Leukemia, Blood and Marrow Transplant (BMT)
- Trial name
- NCT00186381
- Testing
- high dose chemotherapy then autologous hematopoietic cell transplant
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Stanford University
CML, Chronic Myelogenous Leukemia
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
To evaluate efficacy, safety and pharmacokinetic profile of asciminib 40mg+imatinib or asciminib 60mg+imatinib versus continued imatinib and versus nilotinib in pre-treated patients with Chronic Myeloid Leukemia in chronic phase…
- Conditions
- CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic, Hematologic Diseases
- Trial name
- NCT03578367
- Testing
- Asciminib add-on, Imatinib, Nilotinib
- Where
- 30 sites in United States, Austria and 13 more
- Volunteers
- 104 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia
Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing Through"Marrow-Blood Barrier"
Bone marrow consists of a complex hematopoietic cellular component.When the blood progenitor cells differentiate to mature cells, they will exit unassisted to peripheral blood.
- Trial name
- NCT00155844
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML
This phase I/II trial investigates the side effects and best dose of alvocidib when given together with decitabine and venetoclax and to see how well it works in treating patients with acute myeloid leukemia that has come back…
- Trial name
- NCT04493099
- Testing
- Alvocidib Hydrochloride, Decitabine, Venetoclax
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
AML (Acute Myelogenous Leukemia), Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission
This is a single-center, prospective, exploratory clinical study. It plans to enroll 30 adult patients with acute myeloid leukemia (AML) who have achieved first complete remission (CR1) after induction therapy and meet the…
- Trial name
- NCT07644481
- Testing
- CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.